GSK says its experimental targeted cancer therapy “Mo-rez” could become a blockbuster after early trial data showed strong results in hard-to-treat cancers. The drug demonstrated significant tumor shrinkage in patients with advanced ovarian and endometrial cancers, with over 60% of participants achieving at least a 30% reduction in tumor size.
The promising data provide a boost to GSK’s growing oncology division, with research head Hesham Abdullah highlighting confidence in the drug’s potential. Under new CEO Luke Miels, the company is accelerating development efforts, reflecting a faster pace and stronger commitment to advancing new treatments.
GSK is currently running late-stage trials for the drug and plans to launch additional studies soon. The therapy, an antibody-drug conjugate targeting cancer-specific proteins, was licensed from Hansoh Pharma in 2023 and could tap into a rapidly expanding global market for advanced cancer treatments.
Pic courtesy: google/ images are subject to copyright